Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue:
Revenue	$ 66,563	$ 250,646
Operating expenses:
Cost of sales	200
Research and development	345,869	299,921	$ 220,969
Cost of research collaboration	75,000
License expense	5,000	25,050
General and administrative	176,771	139,401	67,046
Operating expenses:	602,840	464,372	288,015
Net operating loss	(536,277)	(213,726)	(288,015)
Loss on extinguishment of debt			(1,501)
Loss on conversion of debt	(100,589)
Loss from remeasurement of development derivative liability	(97,675)	(103,029)	(14,839)
Interest income	418	4,164	5,108
Interest expense	(13,241)	(29,937)	(5,285)
Other income/(expense), net	1,362	(501)	(175)
Net loss before taxes	(746,002)	(343,029)	(304,707)
Income tax expense	352	1,845
Net loss	(746,354)	(344,874)	(304,707)
Other comprehensive income/(loss):
Unrealized gain/(loss) on marketable securities	9	(8)
Foreign currency gain/(loss)	(1,982)	45	(31)
Total other comprehensive (loss)/income	(1,973)	37	(31)
Comprehensive loss, net of tax	$ (748,327)	$ (344,837)	$ (304,738)
Net loss per common share, basic and diluted	$ (8.84)	$ (4.59)	$ (4.90)
Weighted-average number of common shares used in net loss per common share, basic and diluted	84,421	75,163	62,229
Product [Member]
Revenue:
Revenue	$ 15,147	$ 0
Licensing and other revenue [Member]
Revenue:
Revenue	$ 51,416	$ 250,646